Affinity Asset Advisors, LLC Bei Gene, Ltd. Transaction History
Affinity Asset Advisors, LLC
- $579 Million
- Q3 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 35,000 shares of BGNE stock, worth $6.18 Million. This represents 1.36% of its overall portfolio holdings.
Number of Shares
35,000
Previous 110,000
68.18%
Holding current value
$6.18 Million
Previous $15.7 Million
49.93%
% of portfolio
1.36%
Previous 2.14%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.87 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.14 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$914 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$878 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$654 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $18.3B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...